OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

This early phase I trial studies the biological activity of OMO-103 in patients with pancreatic ductal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). OMO-103 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial may help researchers determine how exposure to OMO-103 changes pancreatic tumor cells.

Trial Details

NCT ID
NCT07089940
Phase
EARLY_PHASE1
Sponsor
OHSU Knight Cancer Institute
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Biopsy Procedure
  • Biospecimen Collection
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Myc Inhibitor OMO-103
Locations (sample)
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Must provide written informed consent before any study-specific procedures or interventions are performed
  • Must be ≥ 18 years old at the time of informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Clinically-confirmed diagnosis of locally-advanced or metastatic adenocarcinoma of the pancreas

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →